☰

Michael A. Bauer, Ph.D. - Publications

Affiliations: 
2013 Bioinformatics University of Arkansas at Little Rock, USA 
Tree Info Similar researchers PubMed Report error

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Bauer MA, Ashby C, Wardell C, Boyle EM, Ortiz M, Flynt E, Thakurta A, Morgan G, Walker BA. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma. Haematologica. PMID 32079689 DOI: 10.3324/Haematol.2019.235424  0.314
2019 Ashby C, Boyle EM, Walker BA, Bauer MA, Ryan KR, Dent J, Thakurta A, Flynt E, Davies FE, Morgan G. Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms Blood. 134: 3767-3767. DOI: 10.1182/Blood-2019-130335  0.316
2019 Boyle EM, Davies FE, Deshpande S, Tytarenko RG, Ashby C, Wang Y, Wardell CP, Bauer MA, Johnson SK, Schinke CD, Thanendrarajan S, van Rhee F, Zangari M, Williams L, Facon T, et al. Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma Blood. 134: 4333-4333. DOI: 10.1182/Blood-2019-126679  0.35
2018 Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. PMID 29967379 DOI: 10.1038/S41375-018-0196-8  0.317
2018 Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. PMID 29884741 DOI: 10.1182/Blood-2018-03-840132  0.307
2018 Rasche L, Alapat D, Kumar M, Gershner G, McDonald JE, Wardell CP, Roy Choudhury S, Van Hemert RL, Epstein J, Williams AF, Thanendrarajan S, Schinke CD, Bauer MA, Ashby C, Tytarenko RG, et al. Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma Blood. 132: 3185-3185. DOI: 10.1182/Blood-2018-99-119249  0.301
2018 Bauer MA, Henry M, Patel P, Wang Y, Epstein J, Davies FE, Schinke CD, Zangari M, Thanendrarajan S, van Rhee F, Morgan G, Walker BA, Johnson SK. Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance Blood. 132: 4465-4465. DOI: 10.1182/Blood-2018-99-119131  0.31
2018 Boyle EM, Rosenthal A, Wang Y, Farmer P, Rutherford MW, Ashby C, Bauer MA, Johnson SK, Wardell CP, Weinhold N, Hoering A, Dumontet C, Facon T, Schinke CD, Thanendrarajan S, et al. Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior Blood. 132: 4457-4457. DOI: 10.1182/Blood-2018-99-119113  0.341
2018 Ashby C, Bauer MA, Wang Y, Wardell CP, Tytarenko RG, Patel P, Flynt E, Ortiz M, Dervan A, Gockley J, Mikulasova A, Schinke CD, Thanendrarajan S, Zangari M, van Rhee F, et al. Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma Blood. 132: 408-408. DOI: 10.1182/Blood-2018-99-117359  0.332
2018 Boyle EM, Ashby C, Tytarenko RG, Wang Y, Bauer MA, Deshpande S, Johnson SK, Schinke CD, Thanendrarajan S, van Rhee F, Wardell C, Weinhold N, Facon T, Dumontet C, Morgan G, et al. Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria Blood. 132: 4456-4456. DOI: 10.1182/Blood-2018-99-117193  0.326
2018 Wardell C, Alpe TL, Farmer P, Rutherford MW, Wang Y, Weinhold N, Tytarenko RG, Patel P, Bauer MA, Ashby C, Boyle EM, Schinke CD, Thanendrarajan S, van Rhee F, Zangari M, et al. Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches Blood. 132: 1906-1906. DOI: 10.1182/Blood-2018-99-117103  0.303
2017 Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, et al. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer Journal. 7: e535. PMID 28234347 DOI: 10.1038/Bcj.2017.12  0.318
2017 Walker BA, Wardell CP, Mavrommatis K, Ashby CC, Bauer M, Samur MK, Towfic F, Ortiz M, Flynt E, Trotter M, Thakurta A, Munshi N, Morgan GJ. Identification of Novel Oncogenes and Tumor Suppressor Genes in Newly Diagnosed Multiple Myeloma Blood. 130: 60-60. DOI: 10.1182/Blood.V130.Suppl_1.60.60  0.317
2016 Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, et al. Clonal selection and double hit events involving tumor suppressor genes underlie relapse from chemotherapy: myeloma as a model. Blood. PMID 27516441 DOI: 10.1182/Blood-2016-06-723007  0.312
2016 Chavan SS, Heuck C, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens OW, Weinhold N, Petty N, Steward D, Rasche L, Bauer MA, Ashby C, et al. High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1 Blood. 128: 4416-4416. DOI: 10.1182/Blood.V128.22.4416.4416  0.353
2016 Weinhold N, Chavan SS, Rasche L, Stephens OW, Patel P, Tytarenko R, Ashby C, Stein CK, Bauer MA, Wardell CP, Deshpande S, Buzder T, Molnar G, van Rhee F, Zangari M, et al. Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment Blood. 128: 3278-3278. DOI: 10.1182/Blood.V128.22.3278.3278  0.365
2016 Walker BA, Samur MK, Mavrommatis K, Ashby C, Wardell CP, Ortiz M, Towfic F, Stein CK, Bauer MA, Amatangelo M, Parmigiani G, Yu Z, Trotter M, Avet-Loiseau H, Jackson GH, et al. The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma Blood. 128: 196-196. DOI: 10.1182/Blood.V128.22.196.196  0.364
2015 Bauer MA, Berleant D, Cornell AP, Belford RE. WikiHyperGlossary (WHG): an information literacy technology for chemistry documents. Journal of Cheminformatics. 7: 22. PMID 26110024 DOI: 10.1186/S13321-015-0073-7  0.645
2015 Heuck C, Weinhold N, Peterson EA, Bauer M, Stein CK, Ashby T, Chavan SS, Tytarenko R, Stephens OW, Meissner T, Johann D, van Rhee F, Waheed S, Johnson SK, Zangari M, et al. The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM Blood. 126: 372-372. DOI: 10.1182/Blood.V126.23.372.372  0.316
2015 Heuck C, Chavan SS, Stein CK, Tytarenko R, Weinhold N, Ali S, Miller VA, Thanendrarajan S, Schinke C, Mohan M, Sawyer J, Peterson EA, Bauer M, Ashby TC, Johann D, et al. Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations Blood. 126: 369-369. DOI: 10.1182/Blood.V126.23.369.369  0.329
2015 Weinhold N, Chavan SS, Heuck C, Stephens OW, Tytarenko R, Bauer M, Peterson EA, Ashby TC, Meissner T, Stein CK, Johann D, Johnson SK, Yaccoby S, Epstein J, van Rhee F, et al. High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance Blood. 126: 20-20. DOI: 10.1182/Blood.V126.23.20.20  0.31
2012 Bauer MA, Berleant D. Usability survey of biomedical question answering systems. Human Genomics. 6: 17. PMID 23244628 DOI: 10.1186/1479-7364-6-17  0.635
2012 Isokpehi RD, Udensi UK, Anyanwu MN, Mbah AN, Johnson MO, Edusei K, Bauer MA, Hall RA, Awofolu OR. Knowledge building insights on biomarkers of arsenic toxicity to keratinocytes and melanocytes. Biomarker Insights. 7: 127-41. PMID 23115478 DOI: 10.4137/Bmi.S7799  0.3
2010 Bauer MA, Belford RE, Ding J, Berleant D. ISDB: Interaction Sentence Database. Bmc Research Notes. 3: 122. PMID 20438636 DOI: 10.1186/1756-0500-3-122  0.645
Show low-probability matches.